Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1818338 | 1.00 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| Sulfuric Acid SCHEMBL1815849 | 0.97 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| Sulfuric Acid SCHEMBL29684494 | 0.97 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| Sulfuric Acid SCHEMBL19837752 | 0.97 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| Sulfuric Acid SCHEMBL19900361 | 0.97 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| Sulfuric Acid SCHEMBL1818768 | 0.97 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| Sulfuric Acid SCHEMBL31198220 | 0.97 | TSHR (0.54) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| SCHEMBL27893120 | 0.96 | TSHR (0.53) | TSHRALDH1A1TDP1SMN1; SMN2MMP3 | |
| SCHEMBL1723696 | 0.95 | TSHR (0.59) | TSHRALDH1A1TDP1MMP3MMP9 | |
| SCHEMBL1723878 | 0.95 | TSHR (0.59) | TSHRALDH1A1TDP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. | 2022-05-26 | — | — | US | claimed |
| EP-3470402-B1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX INC (US) | 2021-01-06 | — | — | EP | claimed |
| EP-3470402-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | Pharmatrophix Inc. (US) | 2019-04-17 | — | — | EP | claimed |
| CN-108383804-A | The crystal form of neurotrophin simulated compound and its salt | 特罗菲克斯制药股份有限公司 | 2018-08-10 | — | — | CN | claimed |
| CN-104761515-A | Crystalline forms of neurotrophin mimetic compounds and salts of same | PHARMATROPHIX INC | 2015-07-08 | — | — | CN | claimed |
| US-20130005731-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. (US) | 2013-01-03 | — | — | US | claimed |
| CN-102740856-A | Crystalline forms of neurotrophin mimetic compounds and salts thereof | PHARMATROPHIX INC | 2012-10-17 | — | — | CN | claimed |
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11225467-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | PHARMATROPHIX, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3470402-B1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX INC (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20190263763-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10273219-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | PHARMATROPHIX, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3470402-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | Pharmatrophix Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-9271986-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | PHARMATROPHIX, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| CN-104761515-A | Crystalline forms of neurotrophin mimetic compounds and salts of same | PHARMATROPHIX INC | 2015-07-08 | — | — | CN | disclosed |
| CN-102740856-B | Crystalline forms of neurotrophin mimetic compounds and salts thereof | PHARMATROPHIX INC | 2015-02-18 | — | — | CN | disclosed |
| US-20130005731-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| CN-102740856-A | Crystalline forms of neurotrophin mimetic compounds and salts thereof | PHARMATROPHIX INC | 2012-10-17 | — | — | CN | disclosed |
| EP-2498782-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | Pharmatrophix Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011060262-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | PHARMATROPHIX, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162177-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885TDP1 1390/4885 |
| US-11225467-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885TDP1 1390/4885 |
| US-20190263763-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885TDP1 1390/4885 |
| US-20130005731-A1 | CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS | BDNF, NGF, NTRK2 | TSHR 885/4885ALDH1A1 4396/4885TDP1 1256/4885 |
| US-10273219-B2 | Crystalline forms of neurotrophin mimetic compounds and their salts | BDNF, NGF, NTRK2 | TSHR 971/4885ALDH1A1 4364/4885TDP1 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.